Who is sponsoring NCT00730067?

NCT00730067 is sponsored by University of Aarhus.

What condition does NCT00730067 study?

NCT00730067 studies COPD, Pulmonary Hypertension.

What drugs are being tested in NCT00730067?

Interventions: sildenafil, placebo.

What is the status of NCT00730067?

NCT00730067 is currently WITHDRAWN.

Last reviewed 2012-08-22 · How we verify

Sildenafil for COPD-associated Pulmonary Hypertension. A Randomized Double Blinded Placebo Controlled Study.

NCT00730067 Phase 4 WITHDRAWN

Chronic obstructive pulmonary disease (COPD)can be complicated by an increased pressure in the pulmonary circulation. This worsens the prognosis, but so far it is unknown whether treatment of the increased pulmonary blood pressure betters the patients symptoms. In this study 32 patients with increased pulmonary blood pressure due to COPD will be randomized to 3 months treatment with placebo or sildenafil, which is known to lower the pulmonary blood pressure in other types of pulmonary hypertension. Our hypothesis is that treatment with sildenafil in these patients will improve the functional capacity measured by the distance walked in 6 minutes and life quality.

Details

Lead sponsor	University of Aarhus
Phase	Phase 4
Status	WITHDRAWN
Start date	2012-06
Completion	2012-12

Conditions

COPD
Pulmonary Hypertension

Interventions

sildenafil
placebo

Primary outcomes

6 minute walk test — at base line, after 2 hours and after 3 months

Countries

Denmark